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Abstract
Background:  von  Willebrand  disease  is  the  most  common  inherited  disorder  of  the  coagulation
proteins  in  humans.  There  are  three  types:  1,  2A,  2B,  2N,  2M  and  3.  It  is  associated  with
mutations  on  chromosome  12  in  the  region  p13.2,  encoding  the  von  Willebrand  factor  (VWF),
which is  synthesised  in  endothelial  cells  and  megakaryocytes.
Discussion:  The  VWF  gene  has  been  characterised  using  molecular  biology  techniques,  which
have acquired  an  important  role  in  diagnosis  of  von  Willebrand  disease,  as  well  as  in  the
investigation  of  alterations  in  other  genes,  which  may  be  involved  in  regulating  the  synthe-
sis, processing,  and  secretion  of  VWF.  However,  there  are  still  no  strategies  to  integrate  the
molecular biology  diagnostic  tests  available.
Analysis  of  VWF  multimers  is  a  methodology  that  meets  the  characteristics  for  diagnosis,  but  it  is
not easy  to  standardise.  Considering  that  even  in  tertiary  centres  in  our  country,  von  Willebrand
patients  do  not  have  a  deﬁnitive  diagnosis,  it  is  necessary  to  implement  these  methodologies
to study  and  improve  diagnosis.
Conclusions:  von  Willebrand  disease  is  highly  heterogeneous  due  to  the  molecular  mechanisms
that produce  the  various  clinical  and  laboratory  phenotypes.  In  Mexico  there  are  few  studies
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related  to  this  disease;  therefore  it  is  essential  to  conduct  a  comprehensive  study  including  clin-
ical, basic,  and  special  testing  laboratory  tests,  in  order  to  establish  a  correct  diagnosis,  develop
new therapeutic  approaches,  and  offer  the  appropriate  medical  care  and  genetic  counselling.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Published  by  Masson  Doyma  México  S.A.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Resumen
Antecedentes:  La  enfermedad  de  von  Willebrand  es  el  trastorno  hereditario  más  frecuente  de
las proteínas  de  la  coagulación  en  los  seres  humanos.  Existen  3  tipos:  1,  2A,  2B,  2N,  2M,  y  3.
Está asociada  a  mutaciones  en  el  cromosoma  12,  en  la  región  p13.2,  que  codiﬁca  para  el  factor
de von  Willebrand  (VWF),  el  cual  se  sintetiza  en  las  células  endoteliales  y  megacariocitos.
Discusión:  La  biología  molecular  ha  permitido  la  caracterización  del  gen  del  VWF,  adquiriendo
un papel  importante  en  el  diagnóstico  la  enfermedad  de  von  Willebrand  así  como  en  la  inves-
tigación de  alteraciones  en  otros  genes,  que  pueden  estar  involucrados  en  la  regulación  de
la síntesis,  procesamiento  y  secreción  del  VWF.  Sin  embargo,  aún  no  se  han  integrado  las
estrategias  de  biología  molecular  entre  las  pruebas  de  diagnóstico  disponibles.
El análisis  de  los  multímeros  del  VWF  es  una  metodología  que  cumple  con  las  características
para el  diagnóstico,  pero  no  es  fácil  de  estandarizar.  Tomando  en  consideración  que  aún  en
los centros  de  tercer  nivel  en  nuestro  país  los  enfermos  de  von  Willebrand  no  cuentan  con  un
diagnóstico deﬁnitivo,  es  necesario  implementar  estas  metodologías  para  su  estudio  y  mejorar
su diagnóstico.
Conclusiones:  La  enfermedad  de  von  Willebrand  es  heterogénea  debido  a  los  mecanismos
moleculares  que  producen  los  distintos  fenotipos  clínicos  y  de  laboratorio.  En  México  existen
pocos trabajos  relacionados  con  esta  enfermedad,  por  ello  es  fundamental  realizar  un  estudio
integral que  incluya  aspectos  clínicos,  pruebas  de  laboratorio  básicas  y  especiales,  para  estable-
cer el  diagnóstico  correcto,  desarrollar  nuevos  enfoques  terapéuticos,  y  así  ofrecer  atención
médica y  asesoramiento  genético  adecuados.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Publicado  por  Masson  Doyma  México  S.A.
Este es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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oagulation  disorders  are  hereditary  haemostatic  abnormal-
ties,  and  some  may  present  considerable  diagnosis  and
reatment  difﬁculties.  The  von  Willebrand  disease  is  a
ereditary  disorder  characterised  by  mucocutaneous  haem-
rrhages  of  variable  intensity,  mainly  affecting  the  primary
aemostasis  in  platelet  interaction,  von  Willebrand  factor
VWF)  and  endothelium.  It  implies  changes  in  the  structure,
unction  or  concentration  of  the  VWF,  a  plasmatic  protein
ecreted  by  endothelial  cells  circulating  in  plasma.1
According  to  Vischer  and  de  Moerloose,  in  1926  Erik  Adolf
on  Willebrand  described  a  serious  haemorrhagic  disorder
alled  pseudo  haemophilia  in  a  family  with  prolonged  bleed-
ng  times  despite  having  normal  platelet  counts.1,2 Later  it
as  shown  that  this  disorder  is  it  related  to  a  decrease  in
rocoagulant  activity  in  factor  VIII  of  coagulation  (FVIII),
hich  may  be  compensated  through  an  infusion  of  plasma
r  fractions  of  plasma,  which  evidences  that  the  disease
s  caused  by  the  lack  of  a  plasma  factor.3 In  1971,  it  was
etermined  that  FVIII  and  VWF  were  different  proteins,  and
n  1975  Gralnick  and  Coller4 characterised  the  VWF.  This
c
t
t
tiscovery  was  accompanied  by  a  new  laboratory  test  using
istocetin  to  evaluate  platelet  function  in  this  disease4,5
nd,  in  1985,  the  different  nature  of  the  VWF  was  deﬁnitely
roved  when  describing  the  sequence  of  the  VWF  gene.5,6
on  Willebrand  factor
he  VWF  is  a  multimeric  protein  synthetised  in  cells  of  the
ascular  endothelium,  megakaryocytes  and  platelets  with
2  h  average  life,  codiﬁed  in  a  gene  of  52  exons  (178  kb)
ocalised  in  12p13.2,  and  transcribes  an  mRNA  of  8.8  kb
2813  amino  acids  [aa]).  Currently,  more  than  160  normal
ariants  of  the  gene  structure  are  known.  Its  transcrip-
ion  is  regulated  by  speciﬁc  cell-type  transcription  factors
GATA  and  ETS  proteins),  and  there  are  also  several  repres-
ive  transcriptional  elements  in  the  ascending  sequence  of
he  gene  (Fig.  1).7--9 On  the  other  hand,  there  is  a  partial
opy  in  chromosome  22  (pseudo  gene)  of  exons  23--34  of
he  sequence  of  chromosome  12;  this  non-functional  evolu-
ional  remnant  shows  a  3%  sequence  divergence  in  relation
o  the  gene  of  chromosome  12  and  seems  to  have  been
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Chromosome 12
52 exons
VWF gene, 178 Kb
mRNA, 8.8 Kb
Pre-pro-VWF, ~2813 aa (300- to 350-kDa)
Molecular
weight: Low Intermediate
12 p13.2
High
Figure  1  Representation  of  the  gene,  the  transcription  and
the protein  of  the  von  Willebrand  factor.  The  location  of  the
von Willebrand  factor  gene  is  observed  in  chromosome  12,  the
mature mRNA  and  the  processing  of  the  protein,  from  the  pre-
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apro-von  Willebrand  factor,  to  the  formation  of  multimers  with
high molecular  weight.
generated  more  or  less  during  the  time  when  major  pri-
mates  differentiated  from  monkeys,  which  complicates  the
related  analysis.10 The  VWF  is  a  plasma  glycoprotein  (Gp);
it  is  calculated  that  75--85%  of  the  VWF  freely  circulating
in  the  plasma  derives  from  the  endothelium,  whereas  the
remaining  15--25%  is  stored  in  circulating  platelets  which
originate  from  the  megakaryocyte.1,11
During  the  synthesis  of  the  VWF  the  pre-pro-VWF  protein
is  formed:  it  is  an  initial  product  of  300--350  kDa  (∼2813  aa),
which  contains  a  signal  peptide  of  22  aa,  a  propeptide  of  741
aa  and  a  mature  protein  of  2050  aa.  The  structure  of  the  pro-
tein  of  the  VWF  is  formed  by  several  repeated  domains  in
the  order  D1-D2-D′-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK.  D1,
D2,  D′ and  D3  domains  participate  in  the  regulation  of  forma-
tion  of  multimers,  and  the  D′ and  D3  regions  also  mediate  the
union  with  the  FVIII.  Both  the  A1  and  the  A3  domains  have
collagen-joining  properties.  The  areas  where  the  VWF  joins
the  platelets  are:  in  the  A1  domain  to  the  Gp  Ib/IX  platelet
receptor  (GpIb/IX),  and  in  the  C2  domain  to  the  Gp  IIb/IIIa
receptor  (GpIIb/IIIa),  in  such  a  way  that  each  VWF  monomer
has  domains  which  allow  the  protein  to  join  platelets  ligands
(GpIb/IX  and  GpIIb/IIIa),  in  the  subendothelium  (collagen)
and  in  the  bloodstream  (FVIII).7 The  protein  carries  out
a  post-translational  incorporation,  its  signal  sequences  are
acknowledged  by  the  Sec62/63m  complex  associated  to  the
translocon  in  the  membrane  of  the  endoplasmic  reticulum.
The  propeptide  of  2791  aa  initiates  the  process  of  forma-
tion  of  the  protein  of  the  VWF  and  forms  dimers  through
disulphide  bridges  in  carboxi-terminal  positions,  through  the
disulﬁde  isomerase  membrane.  Later,  glycosylation  takes
place  and  is  transported  to  the  Golgi  apparatus,  where  the
mature  protein  of  2051  aa  forms  disulphide  bridges  in  the
amino-terminal  portions  of  the  dimers,  and  consequently,
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eries  of  multimers  of  different  sizes  ranging  from  one  fun-
amental  225  kDa  unit  to  120,000  kDa  (Figs.  1  and  2).11,12
There  are  2  paths  involved  in  the  secretion  of  the  VWF.
he  constitutive  path  is  related  to  the  synthesis  of  plasma
WF  of  endothelial  origin  stored  in  the  Weibel-Palade  bod-
es  and  the  regulated  path,  which  involves  the  release  of
WF  fully  multimerised,  stored  in  the  alpha  granules,  in
egakaryocytes  and  platelets  (Fig.  2).13,14
The  VWF  shares  these  storage  areas  with  other  proteins
eleased  in  response  to  a  variety  of  physiological  and  phar-
acological  stimuli,  including  thrombin,  shear  stress  and
esmopressin.15 Currently  it  is  known  that  after  its  release
rom  the  cell  where  it  is  synthetised,  multimers  of  extremely
arge  and  high  molecular  weight  VWF  join  the  endothelial
ell  surface  through  interaction  with  the  P-selectin  protein
f  the  Weibel-Palade  bodies.  In  this  area,  VWF  multimers  are
ubject  to  the  shear  stress  of  the  bloodstream,  and  a  physio-
ogical  reduction  of  the  size  of  multimers  through  controlled
roteolytic  fragmentation,  by  the  ADMTS-13  metallopro-
einase  acting  on  multimers  of  the  VWF  in  the  A2  domain,
etween  aa  1605  and  1606.  This  process  originates  the  dif-
erent  forms  of  the  factor,  ranging  from  simple  dimers,  to
he  20  units  forming  the  most  complex  multimer.  Proteoly-
ic  degradation  of  multimers  is  a  normal  event,  since  these
ave  an  elevated  thrombogenic  potential,  through  the  areas
f  interaction  with  platelets,  and  the  wall  of  blood  ves-
els.  Under  homeostasis  conditions  this  reaction  inhibits  the
rowth  of  the  thrombus  forming  the  platelets.16,17
The  structure  of  the  VWF  indicates  that  its  main  role  is
o  join  various  ligands  in  the  bloodstream  and  the  blood  of
he  damaged  vessel  (Fig.  3).  Therefore,  the  3  physiological
unctions  of  the  protein  are:  (A)  mediating  in  the  adhesion
f  platelets  to  the  areas  of  vascular  damage  when  joining
he  GpIb/IX  platelet  receptor,  and  collagen  in  the  vascu-
ar  subendothelium;  (B)  facilitating  platelet  aggregation  by
oining  the  GpIIb/IIIa  platelet  receptor;  and  (C)  joining  the
VIII  and  protecting  it  from  proteolytic  degradation  caused
y  C  protein  activated  in  the  bloodstream.16 Finally,  these
ontacts  reach  a  threshold  leading  to  platelet  activation.
hen,  platelets  adhere  in  a  stable  manner  to  the  wall  of
he  damaged  vessel  and  experience  a  response  of  aggrega-
ion  through  an  event  mediated  by  a  platelet  receptor,  the
pIIb/IIIa.17
pidemiology  of  the  von  Willebrand  disease
he  von  Willebrand  disease  is  the  most  common  hereditary
oagulation  disorder  in  humans,  presenting  global  distribu-
ion,  and  is  also  common  in  other  animal  species  such  as  dogs
nd  pigs.18 Its  prevalence  varies,  depending  on  the  approach
o  deﬁne  the  diagnosis.  In  at  least  2  major  prospective  stud-
es  it  was  found  that  1%  of  the  predominantly  paediatric
opulation  presents  symptoms  and  laboratory  signs  of  von
illebrand  disease.19,20 It  is  believed  that  the  prevalence
f  von  Willebrand  disease  with  haemorrhagic  symptoms  is
pproximately  1  in  1000.21 In  Mexico  there  is  no  epidemio-
ogical  record  of  the  disease;  only  a  few  studies  have  been
eported  from  the  clinical  and  haematological  standpoint,
nd  recently  one  pilot  study  in  133  patients  with  suspected
on  Willebrand  disease.22
258  E.  Hernández-Zamora  et  al.
Constitutive secretion
(pro-VWF
and small multimers) 
Regulated secretion
(VWF multimers)
VWF
mRNA
synthesis 
 
Nucleus Golgi
apparatus
Endoplasmic
reticulum
Weibel–Palade
bodies
VWF storageGlucosydationdimer formation Glucosydation and sulfonation 
multimer formation
  
 
Figure  2  Scheme  of  the  processing  and  secretion  of  the  von  Willebrand  factor  in  endothelium  cells.  The  VWF  is  formed  in  the
endoplasmic reticule,  where  glycosyl  is  dimmed.  Dimers  are  transported  to  the  Golgi  apparatus  and  continue  in  the  secretion
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eneral  information  on  the  von  Willebrand  disease
he  von  Willebrand  disease  is  transmitted  in  an  autosomal
ominant  way;  it  is  the  most  common  hereditary  haemor-
hagic  disorder.  It  is  caused  by  the  decrease  in  the  amount
f  VWF  or  the  presence  of  a  qualitatively  abnormal  VWF
n  circulation.  Rarely,  the  von  Willebrand  disease  may  be
n  acquired  disorder.  The  manifestations  of  the  disease
re  mucosal  cutaneous  bleedings  (epistaxis,  bleeding  gums,
leeding  of  other  mucosa,  ecchymosis,  bleeding  in  dental
rocedures,  etc.).  Its  diagnosis  depends  entirely  on  lab-
ratory  coagulation  tests  and  their  classiﬁcation  demands
pecial  studies  (such  as  determination  of  the  multimers  of
he  VWF).  It  is  important  to  classify  the  type,  since  this  is
mportant  in  choosing  the  treatment.  Most  of  the  time  the
a
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igure  3  Schematic  description  of  the  interaction  of  the  von  Will
he platelet  cap  in  the  haemostasis.  Platelets  adhere  in  a  transito
cting as  a  bridge  between  the  GpIb/IX  receptor  in  the  surface  of  thultimers.  A  small  amount  of  immature  VWF,  dimers  and  small
reatment  is  with  desmopressin,  and  only  in  the  most  severe
ases  is  the  factor  replaced.23
linical  diagnosis
 true,  detailed  and  complete  clinical  history  will  allow
he  doctor  to  make  an  approximation  regarding  the  type
f  alteration  of  the  existing  haemostasis.  It  is  necessary
o  bear  in  mind  that,  while  a  positive  family  history  helps
n  clarifying  the  diagnosis,  a  negative  family  history  does
ot  exclude  the  possibility  of  a  congenital  haemorrhagic
nomaly.  Family  history  may  even  sometimes  fail  to  provide
onclusive  evidence.  Family  history  in  patients  with  von
illebrand  disease  is  often  unclear;  it  must  be  suspected
n  people  with  excessive  mucocutaneous  haemorrhages,
ebrand  factor  and  platelets  activated  during  the  formation  of
ry  manner  to  the  von  Willebrand  factor,  and  their  function  is
e  platelets  and  the  collagen  ﬁbrils  of  the  subendothelium.
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such  as  haematomas  with  no  acknowledge  traumas,  spon-
taneous  onset,  or  minimum  traumas;  also,  haemarthrosis
is  always  abnormal  and  indicates  the  existence  of  a  seri-
ous  coagulopathy.  The  same  can  be  said  about  spontaneous
muscle  haematomas.  They  are  both  an  essential  symp-
tom  of  haemophilia,  and  its  onset  is  very  rare  in  other
haemorrhagic  diathesis,  except  in  severe  von  Willebrand
disease,  especially  type  3  and  likewise,  prolonged  recur-
rent  nose  haemorrhages  and  buccal  cavity  haemorrhages,
including  gum  bleeding  after  brushing  teeth  or  ﬂossing,
or  prolonged  bleeding  after  spot  grinding  or  extractions.
There  may  even  be  haematuria,  excessive  or  prolonged
bleeding  after  a  surgery  or  trauma,  and  affected  women
also  usually  experience  menorrhagia  (generally  from  menar-
che),  and  prolonged  or  excessive  bleeding  after  delivery.
It  is  also  important  to  take  into  consideration  several
other  factors,  some  of  which  increase  the  concentration
of  the  VWF:  pregnancy,  exercise,  trauma,  surgery,  age;
and  its  level  is  higher  in  people  with  blood  type  A  than
in  blood  type  O.  On  the  other  hand,  other  factors  cause
their  decrease:  hyperthyroidism,  renal  failure,  liver  disease,
atherosclerosis,  inﬂammatory  conditions,  cancer,  diabetes
and  hypothyroidism.24,25
Haematological  chemical  laboratory  tests
The  haematological  chemical  laboratory  provides  very  use-
ful  information  that  must  be  interpreted  in  relation  with  the
clinical  context,  which  provides  a  greater  chance  of  a  deﬁ-
nite  diagnosis  and  proper  treatment.  Tests  are  divided  into
basic,  which  allows  us  to  have  a  general  idea  of  the  condition
of  the  patient,  which  include:  blood  cytometry,  bleeding
time,  prothrombin  time,  partially  activated  thromboplastin
time,  and  thrombin  time;  afterwards,  tests  studying  pri-
mary,  secondary  haemostasis  and  ﬁbrinolysis,  as  well  as  tests
targeted  to  the  diagnosis  of  thrombotic  problems.26,27
Basic  tests
Basic  tests  are  platelets  count,  bleeding  time,  prothrombin
time,  partially  activated  thromboplastin  time  and  throm-
bin  time.  The  ﬁrst  2  explore  primary  haemostasis,  while  the
remaining  3 evaluate  secondary  haemostasis.  If  the  results
are  normal,  except  in  rare  cases  haemostatic  disorders  of
clinical  meaning  are  ruled  out.27,28 Its  lengthening  may  be
due  to  deﬁciency  of  a  factor  or  the  existence  of  an  antibody,
inhibitor  of  coagulation  proteins.  The  correction,  or  not,
of  the  test,  when  mixing  the  patient’s  plasma  with  normal
plasma,  will  show  if  it  is  a  deﬁciency  or  an  inhibitor.29
Speciﬁc  tests
Speciﬁc  tests  allow  quantiﬁcation  of  individual  factors.  They
are  used  when  one  or  more  basic  tests  are  altered,  or  when,
while  being  normal,  there  is  clinical  suspicion  of  a  sys-
temic  coagulopathy.  There  are  3  types:  trial,  functional  and
immunological.  The  ﬁrst  type,  in  turn,  may  be  coagulomet-
ric  methods  using  plasmas  with  a  deﬁciency  in  the  factor  to
be  analysed.
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Immunological  methods,  through  antibodies,  assess  the
oncentration  of  the  antigen  of  the  protein  (but  not  its  func-
ion).  A  discrepancy  between  the  levels  obtained  through
unctional  methods  and  immunological  methods  reveals  the
xistence  of  molecular  anomalies.
Within  speciﬁc  tests  there  is  the  activity  of  VWF  as
ofactor  of  ristocetin  (VWF:RCo),  which  depends  on  the
resence  of  large  multimers,  antigenic  VWF  (VWF:Ag),  FVIII
oagulant  (FVIII:C),  ristocetin-induced  platelet  aggregation
RIPA);  most  subtypes  have  a  decrease  in  the  response  to  ris-
ocetin,  which  is  an  agonist  of  the  receptor  of  GpIb-IX  and
he  VWF.  Also,  we  can  include  the  joining  capacity  of  VWF
o  collagen  and  the  FVIII:C  (VWF:CB  and  VWF:VIII)  and  the
nalysis  of  platelet  function  (PFA-100®).  The  latter  may  sub-
titute  the  bleeding  time  in  the  future,  the  use  of  which  is
ery  controversial.
nalysis  of  the  multimers  of  the  von  Willebrand
actor
he  analysis  of  the  multimers  of  the  VWF,  based  on  their
olecular  weight,  is  made  through  electrophoresis.  Multi-
ers  are  seen  using  an  autoradiogram  after  the  incubation
ith  antibodies  against  the  VWF  marked  with  immunoper-
xidase  or  alkaline  phosphatase.  This  technique  allows  a
eﬁnite  diagnosis  of  the  different  types  of  von  Willebrand
isease  based  on  its  multimers  pattern,  and  takes  place  only
n  the  laboratories  referred  to.24,25,30,31
lassiﬁcation  of  the  von  Willebrand  disease
he  last  time  the  International  Society  of  Thrombosis
nd  Haemostasis  (ISTH)  published  its  recommendations
egarding  the  classiﬁcation  of  the  von  Willebrand  disease
as  in  2006,  which  allowed  that  disease  to  be  subdivided
s  quantitative  deﬁciencies  (types  1  and  3)  or  qualitative
eﬁciencies  (type  2),  based  mainly  on  the  phenotype  of  the
rotein  of  the  VWF.25,32
ype  1  von  Willebrand  disease
his  is  the  most  common  form  of  von  Willebrand  disease
nd  represents  nearly  80%  of  all  cases.  Its  transmis-
ion  is  autosomal  dominant,  with  incomplete  penetration.
t  is  characterised  by  a  mild  to  moderate  reduction
0.45--0.05  U/ml)  in  plasma  levels  of  VWF:Ag  and  VWF:RCo.
he  VWF  is  normal  from  the  functional  standpoint,  like  the
ange  of  multimers  of  plasma  VWF,  while  the  plasma  level  of
VIII:C  is  reduced  in  proportion  to  the  level  of  VWF.  These
atients  show  a  spectrum  of  mucocutaneous  haemorrhagic
ymptoms,  the  severity  of  which,  in  general,  is  correlated
ith  the  level  of  deﬁciency  of  the  VWF.  Molecular  stud-
es  indicate  that,  in  addition  to  the  mutations  in  the  gene
f  the  VWF  and  the  ABO  blood  group,  alterations  in  other
enes  may  inﬂuence  the  mild  decrease  of  the  VWF,  such  as
hose  involved  in  the  regulation  of  plasma  levels  of  the  VWF
nd  the  FVIII.33 Although  there  seem  to  be  many  different
utations  causing  the  type  1  disease,  at  least  in  one,  the
utation  originating  in  the  replacement  of  tyrosine  with  cys-
eine  in  the  1584  codon,  it  is  found  in  10--20%  of  patients  in
he  US  and  Europe.25,32,34
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Summary  for  some  type  1  results.  Below  is  a  sum-
ary  of  some  of  the  expected  laboratory  results  for
ype  1:  decreased  levels  of  FVIII,  VWF:Ag  and  VWF:RCo;
ecreased  or  normal  levels  of  FVIII:C  and  ristocetin  (RIPA).
WF:RCo/VWF:Ag  >  0.6.  Normal  levels  of  multimers,  but
ith  partial  quantitative  deﬁciency.  Frequency:  70--80%  and
utosomal  dominant  or  co-dominant  inheritance.25,32--34
ype  3  von  Willebrand  disease
ype  3 von  Willebrand  disease  has  a  prevalence  of  1--3  per
illion  in  most  populations,  although  in  some  places  where
arriage  to  blood  relatives  is  common,  the  prevalence  is
onsiderably  higher.  The  disorder  is  autosomal  recessive  and
ost  parents  of  patients  with  type  3  disease  show  few,  or  no,
aemorrhagic  symptoms;  however,  in  individuals  affected,  it
s  the  most  severe  form  of  the  disease.
In  the  type  3  disease,  the  levels  of  VWF:Ag  and  VWF:RCo
re  always  <  0.05  U/ml,  and  frequently  undetectable.  The
lasma  level  of  FVIII:C  is  reduced  to  levels  from  0.01  to
.10  U/ml.  In  general  there  are  no  plasma  multimers.  These
atients  show  serious  recurrent  mucocutaneous  haemor-
hages,  as  well  as  frequent  musculoskeletal  and  soft  tissue
aemorrhages.  With  the  passing  of  time,  if  the  treatment
s  not  correct,  there  is  chronic  musculoskeletal  damage
nd  patients  of  mean  age  could  require  joint  replacement
urgery.25,32--34
Summary  of  expected  laboratory  results  for  type  3.
arkedly  low  levels  of  FVIII,  VWF:Ag  and  FVIII:C.  Slightly
ow  levels  of  VWF:RCo.  Absent  ristocetin  (RIPA)  and  mul-
imers.  Quantitative  variant  with  decrease  of  FVIII  levels.
requency:  1--5/106 and  autosomal  recessive.
ype  2  von  Willebrand  disease
he  current  classiﬁcation  of  the  von  Willebrand  disease
cknowledges  4  different  qualitative  forms  of  the  disease:
ubtypes  2A,  2B,  2M,  and  2N.25,32--34
ype  2A  von  Willebrand  disease
his  condition  is  characterised  by  loss  of  the  platelet-
ependent  function  of  the  VWF  due  to  the  absence  of
orms  of  the  protein  with  high  molecular  weight.  It  exists
ither  because  of  a  biosynthetic  incapacity  to  produce  these
ultimers  or  because  these  are  produced,  segregated  and
ubsequently  degraded  prematurely  in  the  plasma.  The  typ-
cal  characteristic  of  the  type  2A  disease  is  a  relationship
etween  the  VWF:RCo  and  the  VWF:Ag  (<  0.6),  with  an
bsence  of  VWF  multimers  with  high  molecular  weight  and
ffect  on  the  platelet  agglutination  capacity  induced  by  the
IPA.  Substitute  mutations  causing  the  type  2A  disease  have
een  located  in  D2,  D3,  A1,  A2  domains  and  terminal  C  of
he  VWF  gene.25,32--34
Summary  for  some  results  of  type  2A.  Lower  levels  of
VIII,  VWF:Ag,  VWF:RCo  and  RIPA.  Lower  or  normal  levels  of
VIII:C.  VWF:RCo/VWF:Ag  >  0.6.  Absent  multimers  with  high
olecular  weight,  and  lower  levels  of  those  with  interme-
iate  molecular  weight  (qualitative  deﬁciency).  Frequency:
0--15%  and  codominant  inheritance,  rarely  recessive.ype  2B  von  Willebrand  disease
his  subtype  of  the  von  Willebrand  disease  represents  a  clas-
ic  genetic  feature  of  function  gain.  The  disorder  is  the
d
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esult  of  a  variety  of  dominant  substitution  mutations  in  the
oining  region  of  the  GpIb  in  the  A1  domain  of  the  VWF.  These
utations  increase  the  adherence  capacity  of  the  VWF  to
his  platelet  receptor  and  produce  spontaneous  interactions
etween  VWF  and  the  platelets  in  the  bloodstream,  a  phe-
omenon  that  does  not  take  place  with  normal  VWF.  In  the
lood  samples,  this  interaction  may  be  observed  as  accumu-
ation  of  the  platelets,  and  this  same  abnormality  frequently
roduces  mild  chronic  thrombocytopoenia.  In  other  tests,
he  relation  between  VWF:RCo  and  VWF:Ag  will  often  be
 0.6,  with  a  deﬁcit  of  multimers  of  VWF  with  high  molec-
lar  weight  in  the  plasma  because  these  have  joined  the
latelets.  Another  important  test  to  conﬁrm  the  presence  of
he  type  2B  disease  is  the  proof  of  increase  in  the  platelet
gglutination  capacity  induced  by  the  RIPA;  it  is  detected
y  platelet  aggregation  to  low  concentrations  of  ristocetin
 0.6  mg/ml.
This  set  of  clinical  and  laboratory  ﬁndings  may  also  be
bserved  in  a  rare  hereditary  platelet  disorder,  the  pseudo
on  Willebrand  disease  or  platelet  type  von  Willebrand  dis-
ase.  In  this  dominant  hereditary  feature,  the  substitution
utations  of  function  gain  are  in  the  gene  of  the  Ib  platelet
P  and  cause  an  increase  in  the  afﬁnity  of  adhesion  to  the
1  domain  of  the  VWF.  To  differentiate  it  from  type  2B  of  the
latelet  type  von  Willebrand  disease,  tests  of  agglutination
nduced  by  ristocetin  to  washed  platelets  of  the  patient  and
ixed  with  normal  plasma  are  necessary  (which  will  show  a
reater  reactivity  in  the  case  of  platelet  type  von  Willebrand
isease,  but  not  in  type  2B),  or  the  analysis  of  the  genes  of
he  VWF  and  of  the  GpIb.25,32--34
Results  for  type  2B.  Decreased  or  normal  levels  of  FVIII
nd  FVIII:C.  Slightly  decreased  levels  of  VWF:Ag.  Decreased
evels  of  VWF:RCo.  RCo/VWF:Ag  <  0.6.  Increased  levels  of
IPA.  Absent  or  low  levels  of  multimers  with  high  molecular
eight,  described  as  a  qualitative  variant  with  increase  of
fﬁnity  to  platelets  by  the  GpIb/IX  complex,  a  frequency
 5%  and  codominant  inheritance.
ype  2M  von  Willebrand  disease
his  subtype  is  characterised  by  the  loss  of  function,  equiv-
lent  to  type  2B  of  the  disease.  Most  substitution  mutations
ausing  the  type  2M  of  the  von  Willebrand  disease  have  also
een  located  in  the  A1  domain  of  the  VWF.  In  the  type  2M
isease,  the  relation  between  the  VWF:RCo  and  the  VWF:Ag
s  also  <  0.6,  but  the  characteristics  differentiating  it  from
ype  2B  include  the  absence  of  accumulation  of  platelets
and  therefore  thrombocytopenia)  and  the  presence  of  a
ormal  pattern  of  multimers  in  the  plasma.25,32--34
Results  for  type  2M.  Decreased  or  normal  levels  of  FVIII
nd  FVIII:C.  Slightly  decreased  levels  of  VWF:Ag.  Decreased
evels  of  VWF:RCo.  RCo/VWF:Ag  <  0.6.  Decreased  or  normal
evels  of  RIPA.  Multimers  present.  It  is  a  qualitative  variant
ith  decrease  of  platelet  function,  rarely  presents  and  with
 codominant  inheritance.
ype  2N  von  Willebrand  disease
his  last  qualitative  mutating  form  of  the  von  Willebrand
isease  is  different  from  all  the  previous  ones  in  several
spects.  Its  inheritance  pattern  is  autosomal  recessive,  and
requently  the  only  laboratory  abnormality  is  a  reduced
lasma  level  of  FVIII  (generally  from  0.10  to  0.40  U/ml).
von
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Table  1  Haematological  chemical  tests  and  inheritance  of  the  types  of  the  von  Willebrand  disease.
Diagnosis
Test  or  characteristic Type  1 Type  2A Type  2B Type  2M Type  2N Type  3
FVIII  Decreased  Decreased  Decreased  or  normal Decreased  or  normal Slightly  decreased Markedly  decreased
FVIII:C (U/dl) Decreased  or  normal Decreased  or  normal Decreased  or  normal Decreased  or  normal 0.1--0.4 0.05--0.1
VWF:Ag Decreased  Decreased  Decreased  Decreased  Decreased  or  normal Markedly  decreased
VWF:RCo Decreased  Slightly  decreased Slightly  decreased Slightly  decreased Decreased  or  normal Slightly  decreased
VWF:RCo/VWF:Ag >  0.6 <  0.6 <  0.6  <  0.6  >  0.6  NU
RIPA (mg/ml) Decreased  or  normal
1
Decreased  1 Increased  0.6  Decreased  or  normal
1
Normal  1  Absent
Multimers Normal  APM  absent,  and  PMI
decreased
APM  absent  or
decreased
Present  Present  Absent
Characteristics Partial  quantitative
deﬁciency  of  the  VWF
Qualitative  deﬁciency  Qualitative  with
increase  of  afﬁnity  to
platelets  through  the
GpIb/IX  complex
Qualitative  with
decrease  of  the
platelet  function
Qualitative  with
decrease  of  the
joining  to  FVIII
Quantitative  variant
with  decrease  of  the
FVIII
Frequency (%) 70--78  10--15  <  5%  Rare  Rare  1--5/106
Autosomal
inheritance
Dominant  or
co-dominant
Co-dominant,  rarely
recessive
Co-dominant  Co-dominant  Recessive  Recessive
APM: multimers with high molecular weight; FVIII: factor VIII of coagulation; FVIII:C: factor VIII coagulant; NU: not useful; PMI: multimers with intermediate molecular weight; RIPA:
platelet aggregation induced by ristocetin; VWF: von Willebrand factor; VWF:Ag: VWF antigenic; VWF:RCo: VWF as cofactor of ristocetin.
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ype  2N  von  Willebrand  disease  is  one  of  the  differential
iagnoses  of  an  isolated  level,  from  low  to  moderately  low
n  FVIII.33--37
Patients  may  be  homozygotes  for  substitution  mutations
r  compound  heterozygous  for  2  different  mutations.  They
ay  also  have  mutations  in  the  joining  area  or  a  null  muta-
ion.  Nearly  20  mutations  have  been  described.  Most  are
ocated  between  exons  18  and  20,  which  affect  the  domain
f  joining  to  FVIII.  Other  mutations  have  been  described  in
xons  17  and  21--27,  which  are  outside  the  area  of  joining  to
VIII,  and  are  also  responsible  for  the  decrease  in  the  joining
apacity  between  VWF  and  FVIII.  The  R854Q  mutation  is  the
ost  frequent  mutation  reported.
Results  for  type  2N.  Decreased  levels  of  FVIII  and  FVIII:C.
lightly  decreased  or  normal  levels  of  VWF:Ag.  Normal  levels
f  VWF:RCo  and  RIPA.  Multimers  present.  It  is  a  qualitative
ariant  with  decrease  of  the  joining  to  FVIII,  very  rare  and
ith  an  autosomal  recessive  inheritance  (Table  1).
ariations  and  mutations  in  the  von  Willebrand
actor
llelic  variants  in  the  genome  of  the  VWF  imply  effects  on
he  phenotype,  harmful,  neutral  or  beneﬁcial.  Normal  vari-
nts  are  very  common,  and  around  150  have  been  described
o  date,  such  as  the  c.1451A>G  variant  causing  a  change  of
 histidine  for  an  arginine  in  position  484  of  exon  13,  which
re  related  to  the  different  populations  studied.38,39
There  is  a  great  variety  of  factors  involved  in  the  ori-
in  of  pathological  variations,  due  to  changes  in  only  one
ucleotide,  mainly  in  the  D3  domain  (Fig.  1),  such  as  the
‘Vicenza’’  variant  (c.3614G  >  A)  in  exon  27,  which  causes  a
hange  of  an  arginine  with  a  histidine  in  position  1205  of  the
WF  and  thus  decreases  the  time  that  the  VWF  remains  in
he  plasma;  this  mutation  is  one  of  the  most  studied  muta-
ions  and  is  related  with  type  1  von  Willebrand  disease.40,41
here  is  even  a  molecular  study  of  the  VWF  gene  in  Mexican
ixed-race  patients,  where  3  new  mutations  are  described:
1447Q  in  a  patient  with  type  1  von  Willebrand  disease  and
iabetes;  P2781S  in  a  patient  with  type  2M;  and  P812L  in
nother  patient  with  type  1/2N.22,42 This  high  degree  of  poly-
orphisms  in  the  VWF,  together  with  the  great  size  of  the
ene  and  the  presence  of  a  partial  pseudo  gene,  make  the
omplete  sequencing  of  the  gene  and  interpretation  of  data
ifﬁcult  and  complex.  These  variations  and  their  frequencies
an  be  widely  consulted  in  the  database  of  the  International
ociety  on  Thrombosis  and  Haemostasis-Scientiﬁc  and  Stan-
ardisation  Committee  ISTH-SSC  VWF  Online  (VWFdb).
As  has  been  described,  the  great  number  of  variations  on
he  gene,  and  with  them  their  effects  on  the  structure  and
unction  of  the  VWF,  cause  different  forms  of  von  Willebrand
isease.  In  addition,  other  diseases  may  be  related  to  quan-
itative  and  qualitative  defects  in  the  VWF.  New  evidence
rovides  precise  information  on  the  mechanisms  of  the  dis-
ase  and  the  risk  of  bleeding  associated  with  the  deﬁciency
r  abnormality  of  the  VWF.43reatment
he  treatment  depends  on  the  subtype  of  the  von  Wille-
rand  disease;  however,  therapies  to  prevent  or  control
C
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leeding  recommend:  increasing  plasma  concentration  of
WF  by  endogenous  release  through  the  stimulation  of
ndothelium  cells  with  desmopressin;  likewise,  transfusion
herapy  with  blood  products;  also  using  agents  promoting
aemostasis  and  healing  of  wounds,  but  not  altering  plasma
oncentration  of  VWF  substantially.
Therapeutic  decisions  depend  on  the  type  and  serious-
ess  of  the  von  Willebrand  disease,  as  well  as  the  seriousness
f  the  bleeding,  and  its  actual  or  potential  nature.  The
reatment  is  variable  and  frequently  based  on  the  local
xperience  and  the  doctor’s  preference.  There  are  standard
ecommendations  to  guide  the  treatment  of  von  Willebrand
isease.44,45
iscussion
olecular  biology  has  allowed  the  characterisation  of  the
ene  of  the  VWF,  as  well  as  determining  allelic  variants
nd  mutations.  One  of  the  most  important  applications  of
olecular  biology  is  aimed  at  molecular  diagnosis,  which
s  supported  by  basic  or  clinical  chemical  laboratory  analy-
is  tests,  special  tests  and  genetics.  Molecular  biology  tests
lay  an  increasingly  important  role  in  the  diagnosis  of  the
on  Willebrand  disease,  greatly  improving  the  capacity  to
haracterise  the  genetic  variants  of  the  disease.  Molecular
iology  tests  are  also  used  in  the  investigation  of  other  genes
hich  may  be  involved  in  the  regulation  of  the  synthesis,
rocessing,  secretion  and  control  of  plasma  levels  of  VWF.
ikewise,  given  the  seriousness  of  the  phenotype  of  the  type
 von  Willebrand  disease,  the  genetic  prenatal  diagnosis  of
his  variant  offers  results  to  families  and  their  doctors  to
ake  informed  decisions  regarding  family  planning.  How-
ver,  given  the  complexity  of  the  full  study  of  the  gene,  it  is
ard  to  search  for  a  speciﬁc  mutation,  which  is  why  molec-
lar  biology  strategies  have  not  yet  been  integrated  into
he  available  diagnosis  tests.  On  the  other  hand,  analysis  of
he  multimers  of  the  VWF  is  a  methodology  with  the  neces-
ary  characteristics  for  diagnosis,  although  it  is  technically
emanding  and  not  easy  to  standardise.  Taking  into  consid-
ration  that  in  third  level  centres  in  our  country,  patients
ith  von  Willebrand  disease  do  not  have  a  conclusive  diag-
osis,  it  is  necessary  to  implement  these  methodologies  to
tudy  and  improve  diagnosis.
onclusion
he  von  Willebrand  disease  is  very  heterogeneous,  due  to
he  molecular  mechanisms  producing  the  different  clinical
nd  laboratory  phenotypes.  In  Mexico  there  are  few  works
elated  to  this  disease,  and  therefore  it  is  essential  to  carry
ut  a  comprehensive  study  including  clinical  aspects,  basic
nd  special  laboratory  tests  on  this  type  of  patient  in  our
opulation,  to  establish  a  proper  diagnosis  and  develop  new
herapeutic  approaches  for  treatment,  to  prevent  and/or
orrect  the  related  alterations,  and  offer  correct  medical
are  and  genetic  advice.onﬂict of interest
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